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Abstract
Approximately 4.1 million Americans have been infected with HCV and 45–85% of chronically 
infected persons are unaware of their status. Rapid anti-HCV assays can assist and expedite the 
identification of those unaware of their infection. Performance characteristics of pre-market rapid 
anti-HCV assays (Chembio, MedMira and OraSure) have been evaluated. Their sensitivity (78.9–
99.3%) and specificity (80–100%) varied. Future investigations could include evaluation of rapid 
anti-HCV tests in persons who are coinfected with HCV and HIV, and development of rapid HCV-
antigen tests and nucleic acid tests.
Introduction
The Centers for Disease Control and Prevention (CDC) estimates that 4.1 million Americans 
have been infected with HCV, 75–80% of whom are living with chronic HCV infection [1]. 
CDC recommends routine HCV antibody (anti-HCV immunoglobulin G) testing for persons 
at risk of infection [2]. Yet studies estimate that 45–85% of HCV-infected persons are 
unaware of their status [3–5]. Knowledge of HCV infection status is necessary for persons to 
make health promoting behaviour changes and treatment decisions.
Persons who inject drugs (PWID) account for 58% of all anti-HCV-positive persons in the 
US [1] and CDC estimates that injection drug use (IDU) accounted for 56% of acute 
hepatitis C cases in the US in 2009 [6]. The estimated HCV prevalence among PWID ranges 
from 30% to 70%, depending on frequency and duration of use [7,8], and the incidence 
ranges from 16% to 42% per year [9,10]. Younger PWID (<30 years old) have lower 
prevalence rates, ranging between 10% and 36%, but this still translates to >1/3 of young 
PWID becoming infected [11,12]. At least 50% of persons who have a documented risk 
factor for HCV infection [2] do not receive anti-HCV testing [3,4]. Not only are PWID at 
increased risk for hepatitis C, but they are also at risk for infection by HIV [13]. The 
prevalence of HIV infection among PWID is 6.2% [14] and CDC recommends HCV 
screening of all HIV-infected individuals [15]. The prevalence of anti-HCV immunoglobulin 
G among persons infected with HIV is 24% and increases to 81% when the risk factor 
identified is IDU [13].
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Although PWIDs are at high risk for blood-borne infections such as HCV and HIV, they 
have limited access to health care [16]. Currently, PWID are tested infrequently for anti-
HCV immunoglobulin G and many of those who do test positive do not receive treatment 
because of comorbidities or contraindications, ongoing drug use, or reluctance by their 
physicians to treat. Additionally, many PWID who are tested for HCV using conventional 
assays do not return to receive their results. Point-of-care, rapid HCV testing enables the 
delivery of results at the time of testing [17]. PWID who receive rapid HIV tests have been 
shown to be more likely to be informed of their results than those tested with conventional 
assays, who must return at a later date [18].
Here, we summarize the outcomes of six studies [17,19–23] conducted in the US that 
examined the performance characteristics of rapid anti-HCV tests and propose a research 
agenda to support their adoption in the field.
Evaluation strategy
The six studies use lateral-flow immuno-chromatographic assay devices for testing serum, 
fingerstick blood and oral fluid, and originate from three manufacturers (Chembio [Medford, 
NY, USA], MedMira [Halifax, NS, Canada] and OraSure [Bethlehem, PA, USA]). Rapid test 
performance was evaluated using a standard algorithm recommended by CDC [24]. 
Discordant results were either tested for active HCV infection or for association with 
biological factors such as HIV status, age, sex and race/ethnicity. Active HCV infection was 
determined by quantitative nucleic acid testing (NAT) which detects the presence of the 
HCV RNA.
Rapid assays
Resource constraints, site-specific issues, and specimen type limited the ability to analyse 
each specimen fully, resulting in different sample sizes. The Chembio assay was evaluated in 
three studies using serum [22], fingerstick blood [17,23] and oral fluid [17,23] from PWID 
(n=2,357). The MedMira assay was evaluated in three studies using serum [22] and 
fingerstick blood [23] from PWID (n=1,940). The OraSure assay was evaluated in five 
studies, using serum [20–22], fingerstick blood [20,21,23] and oral fluid [19–21,23] from 
PWID, [17,19,22,23] low-risk individuals [21], and those with signs or symptoms of 
hepatitis C infection [20] (n=5,058).
Reference assays
All of the studies employed the CDC testing algorithm as reference for evaluation of test 
performance. The CDC algorithm uses previously established signal-to-cutoff (s/co) ratios 
unique to each immunoassay to determine the true anti-HCV status. Positivity is defined by 
either reactivity by the conventional enzyme immunoassay (EIA) being above an established 
s/co threshold or reactivity in recombinant immunoblot (RIBA) confirmatory test. Negativity 
is defined by either nonreactivity or negativity by RIBA. Three of the studies also included 
comparison to algorithms specific to the respective manufacturer’s inserts [17,22,23]. 
Additionally, one of the sites in the field study [23] did not utilize the CDC algorithm and 
therefore the reported results were based upon comparison with the conventional EIA only.
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Sensitivity and specificity
Across all studies, sensitivity was defined as the number of positive specimens detected by 
the rapid assay divided by the total number of positive specimens as per the CDC testing 
algorithm. Specificity was defined as the number of negative specimens identified by the 
rapid assay divided by the total number of negative specimens as per the CDC algorithm.
Results
Overall, sensitivity and specificity was highest when using serum specimens as compared to 
fingerstick blood and oral fluid specimens. The sensitivity of the OraSure assay was higher 
than that of Chembio or MedMira (Table 1).
False-negative and false-positive results occurred with all assays and specimen types. The 
MedMira assay yielded the largest proportion of false-negative results (ranging from 8% to 
19%) as compared to the Chembio (0.4–7%) and OraSure (0–6%) assays. In two studies, 
false-negative results were associated with HIV-positivity. In the laboratory setting the 
Chembio assay (adjusted [a]OR 11.0; 95% CI 2.5, 48.2) and the MedMira assay (aOR 4.0; 
95% CI 1.5, 10.2) were more likely to provide false-negative results if the specimens were 
also HIV-positive. In one field setting, the Chembio oral assay (aOR 9.1; 95% CI 2.1, 39.3) 
was more likely to produce false-negative results if the specimens were also HIV-positive.
Discussion
The sensitivity and specificity of rapid anti-HCV assays varied across the six studies. Using 
serum specimens resulted in increased sensitivity as compared with fingerstick blood or oral 
fluid specimens. The OraSure assay had a higher sensitivity than the other 2 assays. In one 
study, the OraSure assay outperformed the conventional EIA [19]. Of 10 specimens with 
discordant results, 5 of 6 specimens that were OraSure-negative and EIA-positive had no 
detectable HCV RNA, and 2 specimens that were OraSure-positive and EIA-negative were 
HCV-RNA-positive. Results from the OraSure test seemed more concordant with NAT than 
from EIA. Whereas rapid assays provide information about anti-HCV immunoglobulin G 
which is a marker of active as well as resolved infection, NATs provide direct evidence of 
active HCV infection. This is an important distinction because between 15% and 33% of 
patients spontaneously clear the virus [25] resulting in an antibody-positive/NAT-negative 
result. Furthermore, HCV-infected patients who achieve sustained virological response after 
antiviral therapy will also demonstrate the same antibody-positive/NAT-negative profile.
False anti-HCV results occurred for all assays in all settings, but false results were not 
significantly associated with the selected demographic variables studied (HIV status, age, 
race/ethnicity or sex). For example, in one study, false-negative results were more likely to 
occur among females when using the MedMira assay [17]. In contrast, female sex was not 
associated with false results for any other assay or evaluation.
False anti-HCV-negative results from the Chembio and MedMira assays occurred more often 
when the specimen was from persons coinfected with HIV, similar to the findings of other 
studies using other assays [26–28]. Of the 43 HIV-positive specimens in one study, 60% 
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were anti-HCV-positive; HIV-positive specimens were between four and eleven times more 
likely to produce a false-negative rapid assay result [22]. This issue is of particular concern 
because the prevalence of HCV infection among HIV-positive persons is high (24%) and, 
conversely, 81% of HIV-positive persons with a history of IDU are anti-HCV-positive [13]. 
HIV–HCV-coinfected persons are at a greater risk of progressing to an AIDS-defining event 
or death than those who are HIV monoinfected [29], and progress to end-stage liver disease 
in less than half the time of HCV-monoinfected persons [30,31].
In one study [23], field staff reported on implications of implementing rapid HCV testing in 
their settings. They reported that rapid testing for anti-HCV overcomes barriers to receiving 
referrals for NAT, medical care and other services. Prior to the study, field staff expressed 
concern that the time required for HCV testing would impede the HIV testing process. 
While they reported that rapid anti-HCV testing was time consuming, they also reported that 
it did not have a negative impact on HIV testing. However, staff reported a need for 
standardized educational materials and counselling messages. Demonstration studies are 
being conducted to evaluate the implementation of rapid anti-HCV assays, new educational 
materials, and counselling messages into HIV testing settings to better understand the impact 
of introducing a new test in an existing setting and how this may influence site operations. 
Further evaluation is required to understand the impact of rapid anti-HCV testing in other 
settings, such as emergency departments and primary care clinics with limited access to 
laboratories.
The OraSure rapid anti-HCV test, recently approved by FDA, enables testing in settings 
where HCV testing has previously been limited. Rapid assays are useful for increasing 
testing opportunities and address the public health problem of under-diagnosis of HCV 
infection. Other benefits include patients being able to receive test results and prevention 
counselling messages during the same visit, and that they can receive expedited referral for 
follow-up testing and care.
In contrast to conventional assays, rapid assays enable specimens (for example, fingerstick 
blood or oral fluid) to be collected and tested at the point-of-care and do not require a 
follow-up visit to receive test results. Of persons who consented to an HIV rapid test, 99% 
received their results and prevention counselling and >94% went to their first clinic 
appointment [26,32,33]. Since rapid HIV testing improves receipt of HIV test results [26–
28,34], access to care and health outcomes [26,32,33], it follows that rapid anti-HCV assays 
can similarly benefit high-risk populations. Rapid, point-of-care testing for HCV can 
expedite and assist in the identification of those HCV-infected persons who are unaware of 
their infection, presenting new opportunities to provide prevention counselling messages and 
referrals for follow-up.
Anti-HCV tests detect both current and past HCV infections, but cannot distinguish between 
them. Persons who have positive anti-HCV test results must also be tested with another 
assay – currently a NAT – to determine the state of infection. NAT is more expensive and 
labour-intensive than anti-HCV testing. However, the recently-developed HCV core antigen 
(HCV Ag) test has the potential to be used as a relatively less expensive reflex test for 
individuals who are anti-HCV-positive and aid in distinguishing resolved from active 
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infections. A quantitative antigen assay, the Architect HCV Ag assay (Abbott, Abbott Park, 
IL, USA), performed on an automated platform, is now commercially available in Europe 
[35]. Several studies in blood donors have shown the detection of HCV core Ag within the 
first 2 weeks of acute infection [36]. The advantages of HCV Ag assay are that it is an 
immunoassay, does not require the same labour-intensive and expensive sample processing, 
as in molecular assays, and its detection confirms active infection; however, the test has a 
lower sensitivity when compared to NAT.
The evaluation studies described in this paper have some limitations. The total number of 
samples tested by the OraSure assay was greater than the number of samples tested by the 
Chembio and MedMira assays, providing OraSure with more opportunities for evaluation. 
Investigators of three of the six studies reviewed [19–21] had financial relationships with 
OraSure. The evaluation of the MedMira assay also was limited in that the platform did not 
allow for oral fluid testing. In one field setting, the MedMira assay was evaluated without 
incorporating the CDC algorithm in the analysis of results [22]. The MedMira rapid assay 
results were compared to results from the screening EIA only and may have resulted in a 
lower sensitivity than if compared to the CDC algorithm. Lastly, none of the studies 
included in the review had more than 50 HIV–HCV-coinfected specimens to refine the level 
of precision required for an acceptable evaluation of such specimens.
Conclusions
Anti-HCV rapid tests can play a significant role in increasing the proportion of HCV-
infected persons who are aware of their infection status, especially among at-risk 
populations. Further studies are needed to evaluate the performance characteristics of the 
rapid anti-HCV assay for specimens from HIV–HCV-coinfected persons. Finally, future 
research should be targeted towards the development of immunoassays for detection of HCV 
antigen and NAT in rapid test formats.
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